Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PCDH17 belongs to the protocadherin gene family, a subfamily of the cadherin superfamily. Additionally we are shipping PCDH17 Proteins (4) and PCDH17 Kits (1) and many more products for this protein.
Showing 10 out of 59 products:
Mouse (Murine) Polyclonal PCDH17 Primary Antibody for ELISA, WB - ABIN4347946
Giefing, Zemke, Brauze, Kostrzewska-Poczekaj, Luczak, Szaumkessel, Pelinska, Kiwerska, Tönnies, Grenman, Figlerowicz, Siebert, Szyfter, Jarmuz: High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. in Genes, chromosomes & cancer 2011
Cow (Bovine) Polyclonal PCDH17 Primary Antibody for WB - ABIN2785751
Szafranski, Schindler, Taudien, Hiller, Huse, Jahn, Schreiber, Backofen, Platzer: Violating the splicing rules: TG dinucleotides function as alternative 3' splice sites in U2-dependent introns. in Genome biology 2008
PCDH17 functions as a tumor suppressor inhibiting Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling and metastasis in breast cancer but is frequently methylated in primary tumors which could be a potential biomarker.
Aberrant methylation of protocadherin 17 is associated with acute lymphoblastic leukemia.
PCDH-17 inhibited metastasis via EGFR (show EGFR Antibodies)/MEK (show MAP2K1 Antibodies)/ERK (show EPHB2 Antibodies) signaling pathway.
DNA methylation (show HELLS Antibodies) in a combination of POU4F2 (show POU4F2 Antibodies)/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting bladder cancer effectively among pathologically varied sample groups.
PCDH17 methylation in serum is a frequent event in early-stage prostate cancer, and it is an independent predictor of BCR (show BCR Antibodies) after radical prostatectomy
PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in clear cell renal cell carcinoma (show MOK Antibodies) patients
PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer.
PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer
This study demonistrated that critical role for PCDH17 in the synaptic development of specific corticobasal ganglia circuits and suggest the involvement of PCDH17 in such circuits in depressive behaviors.
PCDH17 acts as a tumour suppressor, exerting its anti-proliferative activity through inducing apoptosis and autophagy, and is frequently silenced in gastric and colorectal cancers.
Pcdh17 recruits the WAVE complex, Lamellipodin (show RAPH1 Antibodies), and Ena/VASP (show VASP Antibodies) to cell-cell contacts, converting these sites into motile structures.
This gene belongs to the protocadherin gene family, a subfamily of the cadherin superfamily. The encoded protein contains six extracellular cadherin domains, a transmembrane domain, and a cytoplasmic tail differing from those of the classical cadherins. The encoded protein may play a role in the establishment and function of specific cell-cell connections in the brain.